Lupin's Q4 FY 2025-26 Quarterly Results

Result Summary

• Lupin Ltd reported a 4.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 33.0%.
• Its expenses for the quarter were up by 4.2% QoQ and 15.1% YoY.
• The net profit increased 24.4% QoQ and increased 87.7% YoY.
• The earnings per share (EPS) of Lupin Ltd stood at 31.89 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lupin Ltd is a globally recognized pharmaceutical company headquartered in India. It is primarily engaged in the development, manufacture, and sale of a broad range of generic and branded formulations and active pharmaceutical ingredients (APIs). Lupin operates in various therapeutic areas, including cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infectives, and anti-tuberculosis. As of the latest data available, Lupin continues to strengthen its presence in the global pharmaceutical industry through strategic partnerships and acquisitions, although specific recent developments are not detailed in the provided data.

Revenue

Lupin Ltd reported a total income of ₹7615.37 crores for Q4FY26, marking a 4.6% increase from the previous quarter (Q3FY26) and a significant 33.0% rise compared to the same quarter in the previous fiscal year (Q4FY25). This growth in revenue indicates a strong upward trend in the company's financial performance over both quarterly and yearly periods. The company’s revenue generation has shown robust improvement, as evidenced by the increase in these metrics, showcasing a substantial year-over-year growth reflecting its market expansion and sales strategies.

Profitability

The company's profitability has shown remarkable improvement in Q4FY26. Profit Before Tax (PBT) increased to ₹1928.00 crores, which is a 26.7% rise from Q3FY26 and a 115.2% increase year-over-year from Q4FY25. The Profit After Tax (PAT) also saw a substantial increase, standing at ₹1468.67 crores, reflecting a 24.4% growth quarter-over-quarter and an 87.7% increase compared to the previous year. These figures indicate that Lupin has succeeded in enhancing its profitability margins significantly. The tax expenses for the quarter were ₹459.33 crores, which represents a notable 34.5% increase from Q3FY26 and a 304.8% rise from Q4FY25, indicating changes in tax obligations or effective tax rates over the periods.

Operating Metrics

Lupin Ltd has demonstrated strong operational performance as reflected in its Earnings Per Share (EPS), which increased to ₹31.89 in Q4FY26. This represents a 24.2% increase from the previous quarter and an 89.0% rise from the same quarter last year. The increase in EPS corresponds with the improvements in net income, suggesting that the company has effectively leveraged its operations to enhance shareholder value. The total expenses for the quarter stood at ₹5556.03 crores, which increased by 4.2% from Q3FY26 and 15.1% from Q4FY25, indicating scaling operations in line with revenue growth. These metrics collectively highlight the company’s operational efficiency and financial health during the reporting period.